Lyell Immunopharma
LYEL
LYEL
99 hedge funds and large institutions have $278M invested in Lyell Immunopharma in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
31% less capital invested
Capital invested by funds: $404M → $278M (-$126M)
75% less call options, than puts
Call options by funds: $2K | Put options by funds: $8K
Holders
99
Holding in Top 10
3
Calls
$2K
Puts
$8K
Top Buyers
| 1 | +$3.9M | |
| 2 | +$816K | |
| 3 | +$688K | |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$640K |
| 5 |
Invesco
Atlanta,
Georgia
|
+$551K |
Top Sellers
| 1 | -$2.43M | |
| 2 | -$1.96M | |
| 3 | -$1.78M | |
| 4 |
Goldman Sachs
New York
|
-$1.55M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.08M |